Study of New Predictive and Treatment Models for Uterine Cancers Including Cervical Cancer, Endometrial Cancer, and Sarcoma

What this Trial Is About

Researchers are examining new clinical, therapeutic, and prognostic findings to improve treatment models and develop a new algorithm for therapy in patients with uterine neoplasms, including cervical cancer, endometrial cancer, and uterine sarcoma. This observational study focuses on both operable and inoperable uterine malignancies to optimize predictive and therapeutic approaches. The study is sponsored by University Hospital Tuebingen and aims to enhance understanding and management of these cancers. The study involves analysis of circulating tumor cells CTC and disseminating tumor cells DTC, detection of Human Papilloma Virus HPV, Douglas cytology, DNA analysis in blood, proteomic analysis, and sentinel lymph node detection. These diagnostic tests are conducted to gather detailed information about the tumors and their spread. Participants with operable tumors may undergo laparoscopic, robot-assisted, or open radical gynecological surgery as part of their primary therapy. Participants will be involved in various assessments over a 12-month period, including cytology, proteomic, and DNA analyses, as well as urodynamic tests measuring nerve conduction velocity, cystomanometry, urethral pressure profiles, and uroflowmetry before and after surgery. These evaluations help monitor treatment effects and disease progression. The study requires participants to provide informed consent and to be willing and able to complete all study-specific procedures during the observation period.

Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms